178 related articles for article (PubMed ID: 18411771)
1. [Clinical evaluation of supplemental administration of flavoxate hydrochloride in benign prostatic hyperplasia patients with nocturia resistant to an alpha1-adrenoceptor blocker].
Kato S; Kusaka M; Shiroki R; Izumitani M; Asano H; Ooki T; Yanaoka M; Hoshinaga K
Hinyokika Kiyo; 2008 Mar; 54(3):173-7. PubMed ID: 18411771
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker].
Naruoka T; Suzuki Y; Furuta A; Endo K; Sugaya S; Egawa S
Hinyokika Kiyo; 2008 May; 54(5):341-4. PubMed ID: 18546857
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
4. [Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy].
Kamimura N; Hatakeyama S; Kudo S; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Kawaguchi T; Takahashi S; Ohyama C
Hinyokika Kiyo; 2011 Feb; 57(2):71-6. PubMed ID: 21412038
[TBL] [Abstract][Full Text] [Related]
5. Effect of naftopidil on nocturia after failure of tamsulosin.
Oh-oka H
Urology; 2008 Nov; 72(5):1051-5. PubMed ID: 18817955
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
Takahashi S; Tajima A; Matsushima H; Kawamura T; Tominaga T; Kitamura T
Int J Urol; 2006 Jan; 13(1):15-20. PubMed ID: 16448426
[TBL] [Abstract][Full Text] [Related]
7. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
[TBL] [Abstract][Full Text] [Related]
8. [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
Sugino Y; Fukuzawa S; Takeuchi H; Taki Y; Hashimura T; Soeda T; Araki I
Hinyokika Kiyo; 2003 Aug; 49(8):445-9. PubMed ID: 14518379
[TBL] [Abstract][Full Text] [Related]
9. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of naftopidil for nocturia and consequent sleep disturbance in patients with benign prostatic hyperplasia].
Iwaki H; Narita M; Soga H; Sakano Y; Konishi T; Okada Y
Hinyokika Kiyo; 2010 Apr; 56(4):209-13. PubMed ID: 20448444
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
[TBL] [Abstract][Full Text] [Related]
12. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
Gorgel SN; Sefik E; Kose O; Olgunelma V; Sahin E
Int Braz J Urol; 2013; 39(5):657-62. PubMed ID: 24267123
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg.
Oh-oka H
Urol Int; 2009; 82(2):136-42. PubMed ID: 19321997
[TBL] [Abstract][Full Text] [Related]
14. [Etiology of nocturia and clinical efficacy of naftopidil on nocturia in patients with benign prostatic hyperplasia--analysis of frequency volume charts].
Masuda M; Nakayama K; Hiromoto Y; Hirokawa M; Satomi Y; Shiramizu M; Furuhata A; Ikeda A; Kawasaki C
Hinyokika Kiyo; 2004 May; 50(5):309-14. PubMed ID: 15237482
[TBL] [Abstract][Full Text] [Related]
15. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia.
Yoshida M; Inadome A; Masunaga K; Nagata T; Yoshiyasu T
Neurourol Urodyn; 2010 Sep; 29(7):1276-81. PubMed ID: 20878997
[TBL] [Abstract][Full Text] [Related]
17. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
18. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.
Kojima Y; Sasaki S; Shinoura H; Hayase M; Kubota Y; Hayashi Y; Tsujimoto G; Kohri K
Prostate; 2007 Sep; 67(12):1285-92. PubMed ID: 17626248
[TBL] [Abstract][Full Text] [Related]
19. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
[TBL] [Abstract][Full Text] [Related]
20. How frequent are invasive therapies required in patients receiving tamsulosin for benign prostatic hyperplasia? A retrospective long-term study.
Kawabe K; Homma Y; Kubota K; Sozu T;
Int J Urol; 2006 Feb; 13(2):127-31. PubMed ID: 16563136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
